Repeated dialysis needling can cause painful aneurysmal fistulas that must be removed. A new, minimally invasive approach will decrease morbidity amonghemodialysis patients and help improve their ...
In a recent study of older patients with end-stage kidney disease living in Europe, researchers found o ne-third received an ...
Austin, Texas-based TVA Medical received FDA de novo marketing approval for its everlinQ endoAVF System. 1. Using magnetic catheters and radiofrequency energy, the everlinQ endoAVF system creates an ...
SAN JUAN CAPISTRANO, Calif.--(BUSINESS WIRE)--Avenu Medical, Inc. announced today that it has received De Novo marketing authorization from the Food and Drug Administration (FDA) to market its ...
San Juan Capistrano, Calif. -- A new case report published in the Journal of Vascular Surgery provides one of the first known opportunities to directly visualize the permanent and fused connection ...
The FDA-approved Ellipsys® Vascular Access System from Avenu Medical, Inc., became a key focus of attention throughout last week's Controversies in Dialysis Access (CiDA) 15 th Anniversary Meeting, ...
One-third of older patients with end-stage kidney disease received an arteriovenous fistula within 6 months of starting ...
New data suggest that arteriovenous fistulas compared with prosthetic grafts may not be a superior predialysis approach to vascular access for haemodialysis in patients aged ≥80 years. However, the ...
A new study shows significant benefits of the Ellipsys ® Vascular Access System in easily and safely creating durable vascular access for end-stage renal disease (ESRD) patients who require ...
NEW ORLEANS — With the help of nanotechnology, interventionalists might soon be able to create an immediate and permanent percutaneous arteriovenous fistula that has patency and maturation rates ...
WASHINGTON--(BUSINESS WIRE)--The FDA-approved Ellipsys® Vascular Access System from Avenu Medical, Inc., became a key focus of attention throughout last week’s Controversies in Dialysis Access (CiDA) ...